0000904454-19-000460.txt : 20190604
0000904454-19-000460.hdr.sgml : 20190604
20190604140740
ACCESSION NUMBER: 0000904454-19-000460
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190603
FILED AS OF DATE: 20190604
DATE AS OF CHANGE: 20190604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Astley-Sparke Philip
CENTRAL INDEX KEY: 0001376491
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36294
FILM NUMBER: 19876057
MAIL ADDRESS:
STREET 1: C/O BIOVEX GROUP, INC.
STREET 2: 34 COMMERCE WAY
CITY: WOBURN
STATE: MA
ZIP: 10801
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: uniQure N.V.
CENTRAL INDEX KEY: 0001590560
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
BUSINESS ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
BUSINESS PHONE: 1-339-970-7000
MAIL ADDRESS:
STREET 1: PAASHEUVELWEG 25A
CITY: AMSTERDAM
STATE: P7
ZIP: 1105 BP
FORMER COMPANY:
FORMER CONFORMED NAME: uniQure B.V.
DATE OF NAME CHANGE: 20131030
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2019-06-03
0001590560
uniQure N.V.
QURE
0001376491
Astley-Sparke Philip
C/O UNIQURE N.V.
PAASHEUVELWEG 25A
AMSTERDAM
P7
1105BP
NETHERLANDS
1
0
0
0
Ordinary Shares
2019-06-03
4
S
0
400
61.40
D
18872
D
Ordinary Shares
2019-06-03
4
S
0
600
62.97
D
18272
D
Ordinary Shares
2019-06-03
4
S
0
4401
63.80
D
13871
D
Ordinary Shares
2019-06-03
4
S
0
599
64.53
D
13272
D
The shares were sold pursuant to a sales plan adopted by the Reporting Person and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.01 to $61.85. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.35 to $63.28. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.36 to $64.28. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.40 to $64.69. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Christian Klemt, Attorney-in-Fact
2019-06-04